1. Home
  2. BNTC vs EBS Comparison

BNTC vs EBS Comparison

Compare BNTC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNTC
  • EBS
  • Stock Information
  • Founded
  • BNTC 1995
  • EBS 1998
  • Country
  • BNTC United States
  • EBS United States
  • Employees
  • BNTC N/A
  • EBS N/A
  • Industry
  • BNTC Biotechnology: Pharmaceutical Preparations
  • EBS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNTC Health Care
  • EBS Health Care
  • Exchange
  • BNTC Nasdaq
  • EBS Nasdaq
  • Market Cap
  • BNTC 356.6M
  • EBS 393.9M
  • IPO Year
  • BNTC N/A
  • EBS 2006
  • Fundamental
  • Price
  • BNTC $15.36
  • EBS $6.32
  • Analyst Decision
  • BNTC Strong Buy
  • EBS Strong Buy
  • Analyst Count
  • BNTC 7
  • EBS 3
  • Target Price
  • BNTC $24.71
  • EBS $14.33
  • AVG Volume (30 Days)
  • BNTC 40.0K
  • EBS 1.4M
  • Earning Date
  • BNTC 05-14-2025
  • EBS 05-07-2025
  • Dividend Yield
  • BNTC N/A
  • EBS N/A
  • EPS Growth
  • BNTC N/A
  • EBS N/A
  • EPS
  • BNTC N/A
  • EBS N/A
  • Revenue
  • BNTC N/A
  • EBS $965,400,000.00
  • Revenue This Year
  • BNTC N/A
  • EBS N/A
  • Revenue Next Year
  • BNTC N/A
  • EBS $16.07
  • P/E Ratio
  • BNTC N/A
  • EBS N/A
  • Revenue Growth
  • BNTC N/A
  • EBS N/A
  • 52 Week Low
  • BNTC $5.74
  • EBS $4.02
  • 52 Week High
  • BNTC $16.90
  • EBS $15.10
  • Technical
  • Relative Strength Index (RSI)
  • BNTC 61.26
  • EBS 55.78
  • Support Level
  • BNTC $13.01
  • EBS $6.13
  • Resistance Level
  • BNTC $16.55
  • EBS $6.68
  • Average True Range (ATR)
  • BNTC 1.13
  • EBS 0.38
  • MACD
  • BNTC 0.21
  • EBS 0.01
  • Stochastic Oscillator
  • BNTC 72.00
  • EBS 59.06

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

About EBS Emergent Biosolutions Inc.

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Share on Social Networks: